Turn Therapeutics Inc.(TTRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
TTRX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Turn Therapeutics Inc. (TTRX), a Healthcare sector company. TTRX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Turn Therapeutics Inc. reports net income of $-971.0K, free cash flow of $-1.6M. Top institutional holders of TTRX by reported 13-F value include DDFG,, MILLENNIUM MANAGEMENT, Wellington Shields & Co.,, based on the most recent SEC filings. TTRX trades on the Nasdaq exchange and files with the SEC under CIK 2023016. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TTRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Turn Therapeutics Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-971.0K
Free Cash Flow
Q1 2026
$-1.6M
ROIC
Q1 2026
-9.3%
D/E Ratio
Q1 2026
1.19
AI Insight: TTRX Financial Trends
TTRX is pre-revenue with mounting operating losses and negative operating cash flow, though equity has grown to $6M by Q1 2026.
• No revenue recorded across any of the three reported quarters, confirming pre-commercial stage.
• Equity expanded from $1M in Q3 2025 to $6M in Q1 2026, suggesting capital raises offset losses.
• Operating cash outflow deepened from -$1M in Q4 2025 to -$2M in Q1 2026, signaling rising cash burn.
⚠ Total debt appeared at $7M in Q1 2026 with no prior comparable — monitor leverage trajectory closely.
⚠ With no revenue and accelerating cash burn, runway duration is a critical near-term concern.
AI Insight: TTRX Ratio Trends
TTRX swung to deeply negative returns in Q1 2026, with ROE collapsing from 23.8% to -63.5% in a single quarter.
• ROE plunged from 23.8% in Q4 2025 to -63.5% in Q1 2026, a swing of over 87 percentage points.
• ROA turned sharply negative at -20.8% in Q1 2026, versus a positive 9.2% in Q4 2025.
• D/E of 1.19 recorded in Q1 2026 is the only leverage reading available; no prior comparison possible.
⚠ ROIC of -37.2% in Q1 2026 signals capital is being destroyed; operating margin data remains absent across all periods.
⚠ D/E at 1.19 combined with deeply negative ROE raises solvency questions if losses persist beyond Q1 2026.
Get alerted when TTRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Turn Therapeutics Inc. including:
Top Institutional Holders of TTRX
DDFG, Inc
$225.7K70,534 shMILLENNIUM MANAGEMENT LLC
$223.2K69,757 shWellington Shields & Co., LLC
$210.3K65,732 shVANGUARD CAPITAL MANAGEMENT LLC
$158.2K49,450 shTamar Securities, LLC
$96.0K30,000 shBROWN BROTHERS HARRIMAN & CO
$75.8K23,688 shXTX Topco Ltd
$63.1K19,727 shHighTower Advisors, LLC
$63.0K19,684 shRVW Wealth, LLC
$57.6K18,000 shGEODE CAPITAL MANAGEMENT, LLC
$54.9K17,142 sh
| Fund | Value | Shares |
|---|---|---|
| DDFG, Inc | $225.7K | 70,534 |
| MILLENNIUM MANAGEMENT LLC | $223.2K | 69,757 |
| Wellington Shields & Co., LLC | $210.3K | 65,732 |
| VANGUARD CAPITAL MANAGEMENT LLC | $158.2K | 49,450 |
| Tamar Securities, LLC | $96.0K | 30,000 |
| BROWN BROTHERS HARRIMAN & CO | $75.8K | 23,688 |
| XTX Topco Ltd | $63.1K | 19,727 |
| HighTower Advisors, LLC | $63.0K | 19,684 |
| RVW Wealth, LLC | $57.6K | 18,000 |
| GEODE CAPITAL MANAGEMENT, LLC | $54.9K | 17,142 |
More Healthcare Companies
View all Healthcare →Put TTRX on your watchlist
Track score changes the day Turn Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TTRX a good stock to buy?
13F Pro's AI-powered analysis of Turn Therapeutics Inc. (TTRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TTRX are available on the TTRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own TTRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TTRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Turn Therapeutics Inc.'s investment landscape.